Amgen jumps 7.9% on positive Phase 3 Sjögren's trial data

Amgen shares rose 7.9% after the company announced positive topline results from its Phase 3 OASIZ 301 trial evaluating dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease.

The trial demonstrated statistically significant and clinically meaningful improvements in ESSDAI scores that were sustained through Week 48. Side effects were generally mild to moderate during the study.

Dazodalibep is a potential first-in-class CD40L antagonist. There are currently no approved disease-modifying therapies for persistent systemic Sjögren’s disease.